PRMT5 and neoplasm: Notably, those tumors with low PRMT5 levels had uniformly and significantly upregulated PRMT5 expression in a post-chemotherapy recurrent state, implying that PRMT5 may be a key determinant of tumor recurrence and chemoresistance (Figure 2D).